Monday, TransMedics Group Inc (NASDAQ:TMDX) reported revenue of $81.2 million in the fourth quarter of 2023, up 159% Y/Y, beating the consensus of $68.51 million.
The increase was due primarily to the increase in utilization of the Organ Care System (OCS) through the National OCS Program (NOP) and additional revenue generated by the addition of TransMedics logistics services.
The company reported EPS Of $0.12, up from a loss of $(0.21) a year ago, beating the consensus loss of $(0.03).
“2023 was a great year for TransMedics as we achieved 159% revenue growth and launched TransMedics transplant logistics services to provide a more operationally and economically efficient service to our transplant program users,” said Waleed Hassanein, MD, President and Chief Executive Officer.
“We are humbled and excited that the use …